A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Study ID
- NCT05487391
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- QL1706 injection — DRUGQL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
- Vinorelbine Tartrate — DRUGVinorelbine 25mg/m2(D1、D8)Q3W IV, 2-4 cycles
- Paclitaxel — DRUGPaclitaxel 175mg/m2(D1) Q3W IV, 2-4 cycles
- Cisplatin — DRUGCisplatin 75mg/m2(D1)Q3W IV, 2-4 cycles
- Carboplatin — DRUGCarboplatin AUC=5(D1) Q3W IV, 2-4 cycles
- Pemetrexed — DRUGPemetrexed 500mg/m2(D1) Q3W IV, 2-4 cycles
- Placebo — DRUGPlacebo
Study Details
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
Key Dates
- Start date
- Dec 8, 2022
- Status verified
- Oct 2024
- Primary completion
- Aug 31, 2027
- Completion
- May 22, 2029
Study Design
- Enrollment
- 632 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: QL1706 plus Platinum-based chemotherapyQL1706(5mg/kg Q3W IV) plus Platinum-based chemotherapy
- Placebo Comparator: Placebo plus Platinum-based chemotherapyPlacebo(5mg/kg Q3W IV) plus Platinum-based chemotherapy
Primary Outcome Measure
Disease-free Survival (DFS) in the PD-L1 ≥1% Population, Assessed by Investigator. [ Time Frame: Up to approximately 84 months ]
Central Contacts
- Xiusong Qiu86-13918736645
Related Studies
- Molecular Analysis of Thoracic MalignanciesEnrolling By Invitation · Stanford University · Stanford, California
- Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.Recruiting · University of Colorado, Denver · Aurora, Colorado
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona